Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

Tumours are often composed of a multitude of malignant clones that are genomically
unique, and only a few of them may have the ability to escape cancer therapy and grow as …

The nonnegligible reason for the poor prognosis of hepatocellular carcinoma (HCC) is
resistance to conventional chemotherapy. Immunogenic cell death (ICD) is a rare …

Immunotherapy treatments harnessing the immune system herald a new era of personalized
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …

More than a decade after the launch of DNA methyltransferase and histone deacetylase
inhibitors for the treatment of cancer, 2020 heralded the approval of the first histone …

The exploration of an intelligent multifunctional imaging-guided therapeutic platform is of
great significance because of its ideal delivery efficiency and controlled release. In this work …

The bone marrow (BM) is the primary site of adult haematopoiesis, where stromal elements
(eg fibroblasts and mesenchymal stem cells [MSCs]) work in concert to support blood cell …

DNA methyltransferases (DNMTs) are an evolutionarily conserved family of DNA
methylases, transferring a methyl group onto the fifth carbon of a cytosine residue. The …

Nuclear factor erythroid 2-related factor 2 (Nrf2, also called NFE2L2) plays an important role
in cancer chemoresistance. However, little is known about the role of Nrf2 in tumor mutation …

Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates
of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular …